vs
Side-by-side financial comparison of Dexcom (DXCM) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Dexcom is the larger business by last-quarter revenue ($1.3B vs $708.5M, roughly 1.8× Medpace Holdings, Inc.). Dexcom runs the higher net margin — 21.2% vs 19.1%, a 2.1% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 21.6%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 12.0%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
DXCM vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $708.5M |
| Net Profit | $267.3M | $135.1M |
| Gross Margin | 62.9% | — |
| Operating Margin | 25.6% | 21.6% |
| Net Margin | 21.2% | 19.1% |
| Revenue YoY | 21.6% | 32.0% |
| Net Profit YoY | 153.6% | 15.5% |
| EPS (diluted) | $0.67 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $708.5M | ||
| Q3 25 | $1.2B | $659.9M | ||
| Q2 25 | $1.2B | $603.3M | ||
| Q1 25 | $1.0B | $558.6M | ||
| Q4 24 | $1.1B | $536.6M | ||
| Q3 24 | $994.2M | $533.3M | ||
| Q2 24 | $1.0B | $528.1M |
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $135.1M | ||
| Q3 25 | $283.8M | $111.1M | ||
| Q2 25 | $179.8M | $90.3M | ||
| Q1 25 | $105.4M | $114.6M | ||
| Q4 24 | $151.7M | $117.0M | ||
| Q3 24 | $134.6M | $96.4M | ||
| Q2 24 | $143.5M | $88.4M |
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 21.6% | ||
| Q3 25 | 20.1% | 21.5% | ||
| Q2 25 | 18.4% | 20.9% | ||
| Q1 25 | 12.9% | 20.3% | ||
| Q4 24 | 17.0% | 23.4% | ||
| Q3 24 | 15.3% | 21.1% | ||
| Q2 24 | 15.7% | 19.9% |
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 19.1% | ||
| Q3 25 | 23.5% | 16.8% | ||
| Q2 25 | 15.5% | 15.0% | ||
| Q1 25 | 10.2% | 20.5% | ||
| Q4 24 | 13.6% | 21.8% | ||
| Q3 24 | 13.5% | 18.1% | ||
| Q2 24 | 14.3% | 16.7% |
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $4.65 | ||
| Q3 25 | $0.70 | $3.86 | ||
| Q2 25 | $0.45 | $3.10 | ||
| Q1 25 | $0.27 | $3.67 | ||
| Q4 24 | $0.37 | $3.67 | ||
| Q3 24 | $0.34 | $3.01 | ||
| Q2 24 | $0.35 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $459.1M |
| Total Assets | $6.3B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $497.0M | ||
| Q3 25 | $1.8B | $285.4M | ||
| Q2 25 | $1.2B | $46.3M | ||
| Q1 25 | $904.9M | $441.4M | ||
| Q4 24 | $606.1M | $669.4M | ||
| Q3 24 | $621.2M | $656.9M | ||
| Q2 24 | $939.2M | $510.9M |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $459.1M | ||
| Q3 25 | $2.7B | $293.6M | ||
| Q2 25 | $2.6B | $172.4M | ||
| Q1 25 | $2.3B | $593.6M | ||
| Q4 24 | $2.1B | $825.5M | ||
| Q3 24 | $2.0B | $881.4M | ||
| Q2 24 | $2.4B | $763.6M |
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $2.0B | ||
| Q3 25 | $7.5B | $1.8B | ||
| Q2 25 | $7.3B | $1.6B | ||
| Q1 25 | $6.8B | $1.9B | ||
| Q4 24 | $6.5B | $2.1B | ||
| Q3 24 | $6.4B | $2.1B | ||
| Q2 24 | $6.8B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $192.7M | ||
| Q3 25 | $659.9M | $246.2M | ||
| Q2 25 | $303.0M | $148.5M | ||
| Q1 25 | $183.8M | $125.8M | ||
| Q4 24 | $301.4M | $190.7M | ||
| Q3 24 | $199.5M | $149.1M | ||
| Q2 24 | $279.4M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | $188.1M | ||
| Q3 25 | $579.4M | $235.5M | ||
| Q2 25 | $208.9M | $142.4M | ||
| Q1 25 | $96.8M | $115.8M | ||
| Q4 24 | $176.8M | $183.0M | ||
| Q3 24 | $88.3M | $138.5M | ||
| Q2 24 | $213.3M | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 26.6% | ||
| Q3 25 | 47.9% | 35.7% | ||
| Q2 25 | 18.1% | 23.6% | ||
| Q1 25 | 9.3% | 20.7% | ||
| Q4 24 | 15.9% | 34.1% | ||
| Q3 24 | 8.9% | 26.0% | ||
| Q2 24 | 21.2% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | 0.6% | ||
| Q3 25 | 6.7% | 1.6% | ||
| Q2 25 | 8.1% | 1.0% | ||
| Q1 25 | 8.4% | 1.8% | ||
| Q4 24 | 11.2% | 1.4% | ||
| Q3 24 | 11.2% | 2.0% | ||
| Q2 24 | 6.6% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.43× | ||
| Q3 25 | 2.33× | 2.22× | ||
| Q2 25 | 1.69× | 1.65× | ||
| Q1 25 | 1.74× | 1.10× | ||
| Q4 24 | 1.99× | 1.63× | ||
| Q3 24 | 1.48× | 1.55× | ||
| Q2 24 | 1.95× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DXCM
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
